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mitogen-activated protein kinase. Analysis of 132 CF patient 
samples revealed that elevated MIF protein levels correlated 
with poorer lung function. We suggest that targeting MIF by 
small molecular inhibitors might reduce the presence of ex-
tracellular DNA and serve as an adjunct to the use of antimi-
crobial drugs that could ultimately reduce bacterial fitness in 
the lungs during the later stages of CF disease. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Cystic fibrosis (CF) is a lung disease that features 
chronic inflammation of the airways associated with 
bacterial colonization. It is caused by mutations in the 
CF transmembrane regulator (CFTR), a plasma mem-
brane channel that regulates the balance of bicarbonate 
and chloride secretions across the epithelial layer of the 
airways. Patients with CF have an elevated presence of 
plugs containing mucus, DNA, and proteins complexed 
with bacteria that obstruct airflow. These structures ac-
cumulate due to an electrolyte imbalance and a conse-
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 Abstract 
 Neutrophils are the main proinflammatory cell type in chron-
ically infected lungs of cystic fibrosis (CF) patients; however, 
they fail to effectively clear the colonizing pathogens. Here, 
we investigated the molecular composition of non-mucoid 
and mucoid  Pseudomonas aeruginosa -induced neutrophil 
extracellular traps (NETs) in vitro  and compared them to the 
DNA-protein complexes present in the CF sputum. The pro-
tein composition of P. aeruginosa -induced NET fragments re-
vealed that irrespective of the inducing stimuli, NET frag-
ments were decorated with a conserved set of proteins. The 
DNA-protein complexes derived from CF sputum were con-
sistent with NETosis and shared a similar protein signature, 
suggesting that the majority of the extracellular DNA was 
NET derived. The ability of polymorphonuclear leukocytes to 
produce NETs in response to  P. aeruginosa  was driven by 
macrophage migration-inhibitory factor (MIF) by promoting 
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quent inability of the epithelial cilia to beat and mediate 
mechanical clearance. The vast amounts of extracellular 
DNA (eDNA) are traditionally assumed to originate 
from dying cells. Notably, there is evidence that eDNA 
levels correlate with neutrophil counts and can be used 
as an index of inflammation and lung disease severity 
 [1, 2] .
 The discovery of neutrophil extracellular trap (NET) 
release as a unique mechanism of cell death prompted 
us to reevaluate the nature of the eDNA found in CF pa-
tients. NETs are a neutrophil-mediated, innate immune 
response to close-proximity extracellular pathogens  [3] . 
The NET-releasing event, referred to as NETosis, con-
sists of enzyme-triggered decondensation of chromatin, 
rupturing of the nuclear membrane, and subsequent re-
lease of chromatin-containing structures complexed 
with granular or intracellular proteins into the extracel-
lular space  [4–7] . Previous studies implicated NETosis 
as a contributor to the eDNA pool in CF  [8–10] . These 
studies consistently identified that the eDNA is in com-
plex with neutrophil elastase (NE) and myeloperoxidase 
(MPO), two proteins previously described as markers of 
NETosis. Interestingly, Papayannopoulos et al. [9] 
showed that sputum solubilization depended on the re-
lease of active NE from NETs, which facilitated DNase I 
activity by degrading NET-associated histones. Given 
the positive and negative effects that NE has during the 
pathogenesis of CF, Dubois et al.  [8] proposed that reg-
ulating the NE activity by protease inhibitors might pro-
vide means to limit inflammation-induced damage in 
CF. While NE-specific inhibitors are not currently avail-
able for treatment, they are under development, and, 
therefore, this approach seems feasible. However, the 
question that remains is whether adding additional mo-
dalities to the already widely accepted DNase I treat-
ment (e.g., Pulmozyme) is the strategy to take, or wheth-
er novel therapeutic approaches that limit the level of 
NETosis might be a more promising strategy to reduce 
eDNA burden in CF.
 To this end, we were interested in defining endoge-
nous signals or pathways that stimulate NETosis, with 
the expectation that NETosis should be limited or re-
stricted to gain therapeutic benefit. Prior research 
showed that NETosis was triggered by activation of the 
mitogen-activated protein kinase (MAPK) pathway, 
was dependent on reactive oxygen species (ROS), and 
stimulated by cytokines [11] . Since these pathways phe-
notypically mirrored the functional activities of macro-
phage migration-inhibitory factor (MIF), a possible 
correlation between MIF and NETosis was investigated. 
MIF is a ‘danger’ signal released in response to patho-
genic stimuli with potent proinflammatory functions. 
Extracellular MIF is recognized by an array of recep-
tors, including CD74  [12] , CXCR2  [13] , CXCR4  [14] , 
and CXCR7  [15] , to promote cellular survival and 
maintain proinflammatory cytokine synthesis  [16, 17] . 
MIF overrides the anti-inflammatory activities of corti-
costeroids  [18] , which makes it an attractive molecule 
to investigate in the context of neutrophil-rich cortico-
steroid-resistant inflammation in CF. We show evi-
dence that NET production was promoted by MIF in 
an autocrine (or paracrine) manner via potentiating 
MAPK signaling, thus discovering a potential therapeu-
tic target.
 Experimental Procedures 
 Bacterial Strains 
 The non-mucoid  Pseudomonas aeruginosa strains: 2192  nmr 
and the mucoid strains PA581, PA14 mucA, and 2192 were used 
throughout these experiments and provided by Dr. G. Pier 
(Brigham and Women’s Hospital, Harvard Medical School, HMS) 
and were previously described  [19, 20] . The  P. aeruginosa PA14, 
PA14 fliC, PAO1, and PAo1 fliC strains were generously provided 
by Dr. S. Lory (HMS).
 Mice 
 Ethics Statement . All studies were performed in accordance 
with the HMS Institutional Animal Care and Use Committee 
guidelines. The experimental protocols were approved by the In-
stitutional Animal Care and Use Committee of the Harvard Med-
ical Area Office for Research Subject Protection.
 Breeding pairs of  MIF  knockout (KO) mice were obtained from 
Dr. Craig Gerard (Children’s Hospital, Boston) and maintained at 
the Massachusetts School of Pharmacy Animal Care Facility. Con-
trol mice (C57BL6) were obtained from Charles River.
 CF Serum and Sputum Samples 
 Serum samples from CF patients were collected at the Aarhus 
University Hospital during 2002–2004, as previously described 
 [21] . The study was approved by the Ethics Committee of Aarhus 
County and samples were collected with signed informed consent 
 [21] . The analysis of the CF sputum samples was performed using 
discarded patient material as approved by the standing Human 
Research Committee at Partners, Boston, Mass., USA.
 Isolation of Primary Human Neutrophils 
 Polymorphonuclear leukocytes (PMNs) were isolated from 
healthy human donors. Blood (10 ml) was drawn from healthy in-
dividuals with their informed consent using a sodium-heparin 
blood collection kit (Becton Dickinson Vacutainer Safety-Lok 
blood collection set). Blood was inverted to mix with the antico-
agulant agent. A density gradient was prepared using polymorph 
reagent (Axis-Shield) following the manufacturer’s instructions. 
The blood was layered on the gradient and centrifuged at 500  g for 
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30 min at room temperature using a swing bucket centrifuge with-
out brake. Purified PMNs were resuspended in 5 ml of HBSS buf-
fer without Ca 2+ and Mg 2+ buffer (HBSS–/–; Invitrogen, Carlsbad, 
Calif., USA). Immediately prior to adding bacteria, PMNs were 
pelleted at 400  g for 10 min and resuspended in HBSS with Ca 2+ , 
Mg 2+ , and 0.1% gelatin (GHBSS++; Invitrogen).
 Isolation of Primary Murine Neutrophils 
 Bone marrow was flushed out from the femurs and tibias from 
6- to 8-week-old MIF KO and C57BL6 mice. Cells were resuspend-
ed in PBS and 5 m M EDTA, and spun down to pellet at 600  g for 
10 min at 4   °   C. Cell pellets were resuspended in 45% Percoll solu-
tion and layered over a gradient composed of 3 ml 81% Percoll, 2 ml 
62% Percoll, 2 ml 55% Percoll, and 2 ml 50% Percoll. The gradient 
was centrifuged at 1,600  g for 30 min at 10   °   C with no brake. Cells 
were collected from the interface of the 81 and 62% layers. Cells 
were washed and resuspended in 3 ml HBSS–/– buffer, then layered 
over 3 ml of Histopaque 1119 to remove the remaining red blood 
cells. This gradient was spun at 1,600  g for 30 min at 10  °  C. Super-
natant was discarded and cells resuspended in HBSS–/–.
 NET Trapping and Killing Assay 
 1 × 10 6 PMN cells/sample were pelleted and resuspended in 
1 ml of GHBSS++ buffer in 2-ml microfuge tubes and stimulated 
with 20 m M of phorbol 12-myristate 13-acetate (PMA; Abcam) for 
1 h at 37  °  C, agitating with end-over-end rotation  [22] . Plated bac-
terium stocks were inoculated into 5 ml of HBSS–/– buffer such 
that OD 650  = 0.45, resulting in a bacteria suspension of 1 × 10 9 bac-
teria/ml. Following the incubation, designated neutrophil cell 
samples were dosed with bacteria at a multiplicity of infection 
 (MOI) of 0.1, 1, or 10. Samples were incubated for 100 or 200 min 
at 37  °  C with end-over-end rotation. 1 kU of micrococcal nuclease 
(MNase; Worthington Biochemical) was added for the duration of 
the incubation period in a separate series of samples to serve as 
control. Upon completion of the incubation period, aliquots were 
removed from each sample, treated with 100 U DNase at 37  °  C for 
15 min, diluted in series in 96-well, V-bottom microtiter plates us-
ing dilution buffer containing DMEM/F12 media (Invitrogen) 
supplemented with 5% HI-FBS and 0.1% Triton X-100 (MP Bio-
medicals). 10 μl of the diluted samples were spotted onto MacCo-
nkey II plates (Becton Dickinson) and allowed to spread in a streak 
pattern. Pre-infection bacteria stocks were also diluted and plated. 
Plates were allowed to incubate for 10 h at 37   °   C before colonies 
were enumerated. The remaining infection supernatants were 
stored at –20  °  C for subsequent analysis.
 DNA Quantification 
 PicoGreen dsDNA quantitation (Quant-It kit; Invitrogen) was 
used to determine total DNA content present in bacterial infection 
supernatants. The assay was performed according to the manufac-
turer’s instructions and the reaction plate was read on a Tecan In-
finite M200 multimode microplate reader. Fluorescence intensity 
was measured at 520 nm and a linear fit model applied to the stan-
dard curve for analysis.
 Isolation of NET Fragments 
 Neutrophils were seeded at 2.7 × 10 7 cells/dish onto 10-cm 
tissue culture dishes in 10 ml RPMI 1640 media (Invitrogen) sup-
plemented with 10 m M HEPES (Invitrogen). Cells were permitted 
to settle for 30 min at 37   °  C with 5% CO 2 . Cells were then gently 
washed three times with culture media and dosed drop-wise with 
prepared bacterial stock. Infection was conducted in a total vol-
ume of 10 ml of culture media. Infection was permitted for 100 
min in a stationary tissue culture incubator at 37   °   C in 5% CO 2 . 
Following the infection period, NETs from each dish were liber-
ated with appropriate concentrations of MNase enzyme (Thermo 
Scientific) for 30 min at 37   °   C. MNase was then inactivated with 
5 m M EDTA (Invitrogen) per dish and 2× final concentration of 
protease inhibitor cocktail (Roche). Infection supernatants were 
collected in 15-ml conical tubes and cell debris pelleted by cen-
trifugation at 300  g for 5 min at 4  °  C. The supernatants were con-
centrated to 2-ml volumes via spin concentration with Amicon 
3,500 MWCO filter units (Millipore) in a 4  °  C swing bucket cen-
trifuge at 3,500  g . Sucrose gradients were assembled at 4  °  C by first 
adding 3.2 ml of 50% sucrose (50% sucrose w/v in HBSS–/–) into 
a 13.2-ml thin-wall polyallomer ultracentrifuge tube (Beckman 
Coulter), overlaid with 2 ml of 30% sucrose (30% sucrose w/v in 
HBSS–/– supplemented with 2× protease inhibitor cocktail). The 
third sucrose layer of 2 ml of 10% sucrose was added, followed by 
2 ml of infection reaction supernatants. Assembled gradient sam-
ples were ultracentrifuged at 36,000 rpm for 22 h at 4   °   C using a 
SW41 rotor in a Beckman L8-M ultracentrifuge or 1,600  g . 
 Samples were fractionated with a peristaltic pump into ten 1-ml 
fractions per gradient tube. Fractions were analyzed for DNA via 
PicoGreen assay and for protein content via Bradford assay 
( Bio-Rad).
 The protein in each sample was precipitated with trichloroace-
tic acid overnight at –20  °  C. Supernatants were carefully removed 
and washed twice with 100% acetone. The frozen pellets were pro-
cessed for mass spectrometry (MS) analysis at the Taplin Biologi-
cal Mass Spectrometry Core facility (HMS). The functional analy-
sis of the liquid chromatography (LC)/MS-identified proteins was 
carried out using the String v9.05 software.
 Immunoblot Analysis 
 To analyze for the presence of NET-associated proteins, pro-
tein-specific Western blots were performed on sucrose gradient 
fractions. Probing antibodies and blotting conditions included an-
ti-NE (1: 500; Calbiochem) and anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; 1 mg/ml; Abnova). All secondary anti-
bodies were used at a final concentration of 1: 10,000. Blotting con-
trols included active, purified NE (Abcam) as well as soluble cell 
lysates from non-differentiated HL-60 cells, HL-60 cells differenti-
ated with 70 m M dimethylformamide for 5 days, or PMN cell pel-
lets. Soluble lysates were prepared by resuspending cell pellets 
(7.5 × 10 6 for PMNs) in 200 μl radioimmunoprecipitation assay 
buffer (RIPA buffer; Boston BioProducts) with 2× protease inhib-
itor cocktail. Soluble supernatants were transferred and stored at 
–20   °   C. The 4–12% Bis-Tris 15-well NuPAGE gels were loaded 
with non-reduced samples in 1× lithium dodecyl sulfate sample 
loading buffer (Invitrogen) and run for 35 min at 200 V. Gels were 
transferred onto nitrocellulose by running program P2 for 6 min 
in the iBlot transfer system (Invitrogen). The membranes were 
subsequently blocked at room temperature for 1 h in blocking buf-
fer [PBS with 5% nonfat dry milk and 0.001% Tween 20 (Sigma)]. 
The primary antibody incubation followed using PBS-0.001% 
Tween 20 buffer with 0.5% milk containing the desired probing 
antibody at the concentration stated previously. The primary an-
tibody was allowed to incubate with the membrane for at least 2 h 
with rocking at room temperature. Next, the sample was washed 5 
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times for 5 min with PBS-0.001% Tween 20, followed by a 1-hour 
incubation with the appropriate secondary antibody at room tem-
perature with rocking. Blots were developed using the SuperSignal 
West Femto maximum sensitivity substrate (Thermo Scientific). 
Exposures were captured using an Alpha Innotech MultiImage II 
light cabinet and imaging system.
 Analysis of CF Patient Sputum 
 Frozen CF patient sputum samples were thawed on ice before 
being centrifuged at 16,000  g at 4   °   C for 15 min. The soluble frac-
tion was collected. Genomic DNA was digested with DNase I (Sig-
ma) or MNase (Thermofisher) to yield DNA fragments. The reac-
tion was carried out at 37  °  C for 5–10 min and stopped by addition 
of EDTA (5 m M final) and protease inhibitor cocktail (Roche). 
DNA-protein complexes were fractionated by sucrose density gra-
dient ultracentrifugation as described above in the NET fragment 
purification section. All samples were derived from CF patients 
colonized with  P. aeruginosa. 
 Agarose Gel Analysis of NETs 
 To visualize the isolated NET DNA, peak fractions from NET 
isolation gradients were loaded onto 10-well, 1% agarose/ethidium 
bromide gels as follows. Gel was run for 45 min at 120 V in 1× Tris 
acetate running buffer. Gels were then imaged on a UV light box 
and a CCD camera in a dark box.
 Purification of Recombinant MIF  
 Recombinant MIF (rMIF) protein was produced in  Escherichia 
coli BL21 Star (DE3) cells (Invitrogen) after induction with 1 m M 
isopropyl-β- D -thiogalactopyranoside for 3.5 h  [17] . Bacterial cells 
were pelleted by centrifugation in a Beckman Allegra 6R centrifuge 
(3,000 rpm, 15 min, ambient temperature). Approximately 1 g of 
bacterial pellet was resuspended in 5 ml of 50 m M Tris (pH 8.5), 
50 m M KCl, 5 m M magnesium acetate, and 0.1% sodium azide, and 
sonicated. The lysate was centrifuged at 15,000 rpm for 20 min, 
then filtered through a Millipore Steriflip vacuum filtration system 
with 0.2-μ M membranes. The filtered lysate was loaded onto a 5-ml 
QHP HiTrap anion exchange column in a negative chromatogra-
phy mode such that rMIF remained unbound. The rMIF was buf-
fer exchanged and concentrated by loading onto a Mono S cation 
exchange column and eluted with a linear gradient.
 Analysis of ROS 
 0.5 to 1 × 10 6 purified murine PMNs per sample were exposed 
to  P. aeruginosa PAO1 in the presence of horseradish peroxidase 
(Sigma) and luminol. Released ROS were monitored for up to 1 h 
using a Tecan luminescence reader  [23] .
 Analysis of MIF Levels 
 MIF levels in CF patient sputum or serum samples were quan-
tified using an MIF ELISA kit (R&D Systems) according to the 
manufacturer’s instructions.
 Confocal Imaging 
 Purified PMNs were stimulated with PAO1 at MOI 10 and in-
cubated at 37   °   C in 4-well slides (Lab Tek, ThermoFisher Scien-
tific). Cells were fixed with 4% formalin for 15 min, washed with 
HBSS–/–, permeabilized with HBSS–/–, 0.2% Tween 20. DNA was 
visualized by SYTOX Green according to the manufacturer’s in-
structions (Invitrogen). Samples were imaged using an LSM 510 
META laser scanning confocal microscope (Zeiss). Alexa 488 was 
detected using the 488-nm excitation line and a 500- to 530-nm 
band-pass filter. Alexa 555 and Alexa 647 were excited at wave-
lengths of 543 and 633 nm, and detected using a 560- to 615-nm 
band-pass filter and a 650-nm long-pass filter, respectively.
 Statistical Analysis 
 Data were analyzed with GraphPad Prism 5.0 software (Graph-
Pad Software Inc.). Sample distribution was analyzed for normal-
ity. When appropriate, data were compared using Student’s t test 
or one-way ANOVA followed by Bonferroni’s post hoc test. Linear 
regression analysis was applied to determine potential associations 
between MIF serum protein levels and forced expiratory volume 
in 1 s (FEV 1 ), forced vital capacity, and forced expiratory flow be-
tween 25 and 75% as dependent variables.
 Results 
 Both Non-Mucoid and Mucoid P. aeruginosa Strains 
Stimulate the Release of NETs That Share a Common 
‘Core’ Proteome 
 To examine whether the non-mucoid and the mucoid 
 P. aeruginosa isolates stimulate neutrophils to NETose, 
human PMNs were stimulated with bacteria at MOI 1 or 
10, and eDNA was released by partial MNase digest and 
quantified. The mucoid (2192, PA581, and PA14 mucA) 
and the non-mucoid strains (PAO1, 2192 nmr, and PA14) 
of  P. aeruginosa -triggered eDNA release. The levels of the 
released eDNA were significantly higher when the PMNs 
were stimulated with the non-mucoid strains when com-
pared to the mucoid  P. aeruginosa ( fig.  1 a, b). Since 
 Fig. 1. Non-mucoid or mucoid  P. aeruginosa strains induce NET 
release.  a Purified human PMNs were stimulated with non-mu-
coid or mucoid  P. aeruginosa  strains at MOI 1 or 10 and eDNA 
was quantified 1 h after exposure. Results are representative of 3 
independent experiments. Pair-wise comparisons were carried out 
using Student’s t test.  *  p < 0.05.  b Representative image of  P. ae-
ruginosa PAO1-induced NETosis. Purified murine PMNs were ex-
posed to PAO1 for 1 h at MOI 10, fixed with formalin, permeabi-
lized with 0.3% Tween 20/PBS and stained with SYTOX green.  c 
The levels of NETosis induced by  P. aeruginosa PAO1/PAO1 fliC 
(MOI 6) or PA14/PA14 fliC (MOI 10) were compared. The reac-
tion supernatants were harvested at different time points after the 
onset of reaction and eDNA was quantified. Results are represen-
tative of 2 independent experiments. Pair-wise comparisons were 
carried out using Student’s t test.  *  p < 0.05.  c NETosis was induced 
by  P. aeruginosa PA01 and PA581 mucA strains. NET-containing 
fractions were defined as fractions that were rich in HMW eDNA 
and NE. The Western blotting analysis for NE is compared to the 
DNA present in the individual sucrose density gradient fractions. 
These data are representative of at least 3 independent experi-
ments.  d Representative images of NETs induced by PAO1 at MOI 
10. PMNs were fixed and permeabilized prior to DNA staining. 
(For figure see next page.)
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 P.  aeruginosa loses flagella during colonization while ac-
quiring mucoid characteristics, the contribution of flagel-
lin in inducing NETosis was analyzed. Two pairs of strains 
were used in these experiments: PAO1 and PAO1 fliC 
mutant or PA14 and PA14 fliC mutant ( fig. 1 c). In the 
absence of flagellin, the PAO1 fliC mutant showed a ten-
dency to induce less eDNA release, but this difference did 
not reach significance. In contrast, when the PA14 and 
PA14 fliC pair was compared, the flagellin-deficient mu-
tant induced significantly lower eDNA release, suggest-
ing that the presence of flagella triggers NETosis.
 To verify that the eDNA were NET fibers, the NET 
DNA fragments were purified by sucrose density gradient 
ultracentrifugation followed by Western blotting for NE, 
a marker for NETs  [4, 9] ( fig. 1 c). When the individual 
fractions were examined for reactivity with NE-specific 
antibody, a positive signal correlated with the presence of 
DNA ( fig. 1 c). In addition, fluorescent microscopy analy-
sis was carried out to observe netting PMNs in response 
to PAO1 stimulation ( fig. 1 d).
 To further characterize the composition of NETs re-
leased in response to stimulation with the different  P. ae-
ruginosa strains, equal concentrations of NET DNA-con-
taining samples were precipitated and the proteins were 
characterized using LC-MS/MS. Fractions enriched for 
high-molecular-weight (HMW) DNA and NE were 
pooled and analyzed. While 24 NET-associated proteins 
were previously reported  [24–26] , the number of proteins 
identified in this study ranged from 45 to 80, depending 
on the nature of the stimuli (online suppl. table  1; 
for  all  online suppl. material, see www.karger.com/
doi/10.1159/000363242). There were 33 common NET-
associated proteins when NETosis was triggered by the 
three different  P. aeruginosa strains. The majority of hu-
man proteins attached to NETs were shared between the 
non-mucoid and the mucoid  P. aeruginosa strains (χ 2 
analysis for trend, p = 0.0012). For example, more than 
90% of the identified NET-associated host proteins that 
were released in response to the  PAO1 stimulation were 
identical to the NET-associated proteins released in re-
sponse to the mucoid  P. aeruginosa 581 (an alginate-pro-
ducing PAO1 strain) stimulation. Twenty-two proteins 
were unique for the  PA581 -stimulated NETs ( fig. 2 ) and 
39 proteins were unique for the  2192 NETs ( fig. 2 ). Func-
tional analysis of the proteome showed that the  P. aeru-
ginosa -induced NETs were decorated with the ‘classical’ 
NET members (e.g., histones, elastase, lysozyme, MPO, 
and superoxide dismutase), similar to the previously pub-
lished PMA-induced NETs  [26] . The NET proteins could 
be segregated into different functional categories, such as 
nucleic acid binding, enzymes, structural proteins, and 
proteins with previously reported antimicrobial activity 
(online suppl. table 1). String-based analysis for protein-
protein interactions showed that the NET proteome is 
significantly enriched for protein associations (p = 0.01), 
illustrating a conserved core of DNA-associated proteins 
that represent the ‘NET signature’ ( fig. 2 b).
 CF Sputum Is Enriched for NETosis 
 To compare the in vitro generated NETs with the 
DNA-protein complexes in CF sputum, LC/MS-MS 
analysis was executed using preparations enriched for 
NET structures ( fig. 3 ). All proteins identified with more 
than 3 unique peptides per sequence were considered 
for analysis. Fifty-eight of the identified proteins that 
passed the inclusion criteria were shared between pa-
tients 1, 2, and 3 (χ 2 analysis for trend, p = 0.001), dem-
onstrating a significant degree of commonality ( fig. 3 ). 
The NET markers elastase, MPO, and lysozyme  [25] 
were present among the 55 proteins identified, suggest-
ing that the eDNA in CF is organized in NETs. These 
findings are in agreement with the recently published 
observations that the CF-derived DNA carries NE and 
MPO  [8, 9] and has a physical appearance similar to that 
of NETs when visualized by atomic force microscopy 
 [10] . Our data expand the existing knowledge by provid-
ing a list of proteins that commonly present in CF spu-
tum ( table 1 ).
 To verify the LC-MS/MS findings, sputum samples 
from 6 additional CF patients were fractionated to yield 
enriched DNA-protein complexes. Three NET-associat-
ed protein markers, namely NE, transketolase (TK), and 
glyceraldehyde phosphate dehydrogenase (GAPDH), 
were analyzed. Albeit to a different degree, all patient 
samples were positive for NE, TK, and GAPDH, con-
firming that LC-MS/MS identified NET-associated pro-
teins were present in the fractionated CF sputum. To 
demonstrate that the NE and GAPDH occurrence cor-
related with the DNA, the CF patient sputum sample 
which had low levels of DNA (<8 ng/ml of sputum) was 
fractionated and analyzed for NET-associated proteins 
( fig. 3 b). When DNA levels were low, there were only 
trace amounts of NE and GAPDH ( fig. 3 c), suggesting 
that NE and GAPDH signals correlated with DNA.
 Distinct Sensitivity of the Different P. aeruginosa 
Strains to NET Capture and Killing 
 To determine the functional significance of NETs, in 
vitro experiments addressing NET-mediated capture of 
 P. aeruginosa and killing were carried out. Because the 
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previously reported PMA-induced NETs had similar 
core protein composition to the  P. aeruginosa -induced 
NETs  [26] , we exposed neutrophils to PMA and analyzed 
the survivability of the non-mucoid (e.g., PAO1) versus 
the mucoid (e.g., 2192)  P. aeruginosa strains in the pres-
ence or absence of endonuclease (e.g. MNase;  fig.  4 ). 
Upon completion of the incubation period, all samples 
were treated briefly (15 min) with DNase I to disperse 
trapped bacteria ( fig.  4 ). Aliquots of the reaction were 
plated before and after DNase I treatment to allow dif-
 Fig. 2. NET-associated proteins released in response to stimulation 
with the different  P. aeruginosa strains share a high degree of com-
monality.  a Venn diagram displaying the numbers of shared and 
unique NET-associated proteins. The total number of identified 
proteins is expressed under each stimulant.  b Functional analysis 
of the shared NET-associated proteins or ‘NET core proteins’. Dif-
ferent line colors represent the types of evidence for the associa-
tion. Green lines indicate interactions based on experimental data, 
the red lines indicate associations based on KEGG database search-
es (colored in the online version only). Each circle represents an 
individual protein identified by LC/MS-MS analysis that had >10% 
unique amino acid sequence coverage. The available crystal struc-
ture of the identified protein is shown inside the circle. The image 
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ferentiation between the trapped and killed bacteria  [27] . 
The samples that were treated with MNase for the dura-
tion of the experiment had no intact NETs and served as 
controls since bacterial trapping in the MNase-treated 
samples did not occur. These experiments suggested that 
NETs aggregated and killed 50% of the non-mucoid 
PAO1 strain ( fig. 4 a) but only trapped 20% of the mucoid 
strain 2192 and, consequently, failed to kill the mucoid 
strain 2192 ( fig. 4 b). These findings suggest that NETs 
were not effective at protecting against the late  P. aerugi-
nosa  colonizers. While these data confirm earlier pub-
lished observations  [28] , our experimental approach dis-
 Fig. 3. CF sputum is NET rich.  a Venn dia-
gram displaying the numbers of shared and 
unique NET-associated proteins identified 
in 3 CF patient samples. NET fragments 
were purified from CF sputum samples 
from 3 patients using sucrose gradient ul-
tracentrifugation. DNA was fragmented by 
brief DNase I treatment and NET complex-
es enriched using sucrose gradient ultra-
centrifugation. HMW DNA-containing 
fractions were precipitated, and proteins 
identified by LC/MS-MS. Protein sequenc-
es which displayed 3 or more unique pep-
tides were considered as true hits.  b The 
presence of NET proteins depends on 
DNA. CF sputum samples containing high 
and low DNA levels were fractionated us-
ing sucrose density gradient ultracentrifu-
gation, DNA was quantified in the individ-
ual gradients samples. Samples 3–6 were 
subsequently analyzed for NET markers, 
NE and GAPDH, using Western blotting. 
 c  Western blotting analysis for NET pro-
tein markers in samples derived from 6 ad-
ditional CF patients. CF sputum samples 
from 6 CF patients were fractionated using 
sucrose density ultracentrifugation and 
DNA was quantified. The HMW DNA-
rich fractions were precipitated and ana-
lyzed for NE, TK, and GAPDH. Purified 
NE or total neutrophil lysates were used as 
control samples for Western blotting. 
a
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tinguishes between trapping and killing of  P. aeruginosa 
by NETs, an issue which was not addressed in the prior 
research and provides insights into the resistance mech-
anisms, namely resistance to capture.
 MIF Promotes NET Release 
 Because NETs failed to kill the mucoid  P. aeruginosa , 
we next examined the molecular mechanism of NETosis 
with the objective to identify host-specific molecular tar-
gets that can be manipulated in CF to lower the levels of 
extracellular DNA and facilitate sputum solubilization. 
Recent screening for intracellular pathways that stimu-
lated NET release showed that activation of the MAPK 
p44/p45 pathway promoted NETosis over apoptosis  [29] . 
Since we and others have reported that the endogenous 
cytokine MIF is rapidly released in response to infectious 
challenge and stimulates MAPK activation  [17, 30] , the 
influence of MIF on NETosis was evaluated  [31] . When 
MIF-deficient PMNs were purified from MIF KO mice 
and exposed to  P. aeruginosa  PAO1 , the resulting MAPK 
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 Common NET-associated proteins present in the 3 CF patient sputum samples were grouped depending on function. All listed proteins were identified 
using two or more unique peptide sequences. Previously reported NET-associated proteins are italicized  [24–26] . P. aeruginosa-induced NET-associated 
proteins described in this study are in bold.
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activation was sustained upon reconstitution with 100 ng 
rMIF as evident by the elevated phosphorylation state of 
p42/p44 30 and 60 min after infection ( fig. 5 ). Reconsti-
tuting rMIF of MIF-deficient PMNs promoted ROS re-
lease in response to  P. aeruginosa and this was ablated by 
the presence of the MEK inhibitor UO126 ( fig. 5 ). Treat-
ment with 100 ng rMIF alone induced a mild increase in 
ROS over the background in the absence of infectious 
agent. When 100 ng rMIF was added to samples in the 
presence of  P. aeruginosa , the released ROS was signifi-
cantly elevated compared to the background. Next, MIF-
deficient and MIF-sufficient [i.e. from wild-type (WT)] 
PMNs were stimulated with the  PAO1  strain and the lev-
els of NETing PMNs quantified. Fluorescent confocal 
imaging was used to evaluate the DNA morphology of 
 P. aeruginosa -activated PMNs. WT PMNs formed DNA-
rich elongated structures after stimulation with  P. aeru-
ginosa strain  PAO1 at MOI 10 ( fig. 5 ). Several PMN nu-
clear phenotypes could be distinguished: donut-shaped 
nuclei, specific for resting PMNs; delobulated nuclei, 
specific for the nuclei that undergo chromatin remodel-
ing; diffuse-shaped nuclei, specific for the early stage of 
NETosis, and actual NETs, with elongated chromatin 
structures, consistent with previously described stages 
for DNA reorganization ( fig. 6 a, b)  [22, 32, 33] . Upon 
quantification of the four distinct stages of NETosis, 
MIF-sufficient PMNs released significantly more NETs 
than MIF-deficient PMNs ( fig. 6 c). Infected WT PMNs 
that casted NETs accounted for 35% of the total PMN 
population whereas only 15% of the MIF-deficient PMNs 
released NETs (light blue sectors in the online version of 
 fig. 6 c; t test p < 0.05). To determine whether inhibition 
of MIF affected NETosis, human PMNs were pretreated 
with a small molecule, irreversible inhibitor of MIF [4-io-
do-6-phenylpyrimidine (IPP)] and stimulated with  P. ae-
ruginosa PAO1 at MOI 10  [34] . Of the DMSO-treated 
PMNs, 95% showed signs of NET release in response to 
 P. aeruginosa stimulation whereas 37% in the 4-IPP-
treated PMNs were NET releasing (including the PMNs 
that presented with diffuse nuclear appearance). Of the 
4-IPP-treated PMNs, 54% preserved their donut-shaped 
nuclei as opposed to none in the DMSO control (t test 
p < 0.05;  fig. 6 d).
 Elevated MIF Protein Levels Correlate with Poor Lung 
Function in CF Patients 
 Prior reports have shown that patients who carry MIF 
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 Fig. 4. Non-mucoid and mucoid  P. aerugi-
nosa strains show distinct sensitivity to 
NET-mediated killing. Purified human 
PMNs were pretreated with PMA to induce 
NETosis and exposed to PAO1 ( a ) or  2192 
 ( b )  at MOI 0.1 for 100 or 200 min. The en-
donuclease presence in the reaction mix-
ture is indicated (+/–). Results are repre-
sentative of 2 independent experiments. 
Samples were compared with one-way 
ANOVA for variance and significant dif-
ferences indicated with asterisks. 
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hibit less colonization by  P. aeruginosa and milder CF dis-
ease, suggesting that regulating MIF levels or MIF activity 
may confer therapeutic benefit for CF patients  [35] . To 
expand on these findings, we analyzed a cohort of serum 
samples from 117 Caucasian CF patients  [21] for MIF pro-
tein levels and correlated those with disease pathology. 
The mean MIF levels in CF patient sera (6,328 ± 2,891 pg/
ml) were significantly increased compared to the MIF lev-
els in pooled human serum from 10 healthy individuals 
(2,400 ± 900 pg/ml; p < 0.0001;  fig. 7 ). MIF levels in CF 
serum samples ranged widely (from 562 to 14,299 pg/ml). 
























































































100 ng rMIF + UO126
100 ng rMIF
 Fig. 5. MIF promotes MAPK activation in 
neutrophils.  a Purified mouse MIF-defi-
cient PMNs were infected with PAO1 and 
lyzed with RIPA buffer supplemented with 
protease inhibitors 5, 30, and 60 min after 
the infectious challenge. Separate sets of 
samples were collected with and without 
infection to monitor baseline and  P. aeru-
ginosa -induced phosphorylation of MAPK 
(p42/p44). 100 ng rMIF was supplemented 
to MIF-deficient PMNs during infection to 
monitor MIF-driven MAPK activation 
during infection. The bottom panel repre-
sents densitometry analysis of the Western 
blotting images. The percent change of 
MAPK activation was calculated for the 
rMIF-treated, infected samples compared 
to non-rMIF-treated, infected samples. 
The images are representative of duplicat-
ed experiments.  b MIF-deficient PMNs 
were supplemented with different concen-
trations of rMIF, infected with  P. aerugi-
nosa, and ROS release monitored. Samples 
were compared with one-way ANOVA, 
and significant differences are indicated 
with asterisks. Data are representative of 3 
independent experiments.  c MIF-deficient 
PMNs were supplemented with 100 ng 
rMIF, treated with the MEK inhibitor 
UO126, and the levels of ROS monitored 
after the infectious challenge with  P. aeru-
ginosa . Samples were compared with one-
way ANOVA and significant differences 
indicated with asterisks. Data are represen-
tative of 2 independent experiments. 
 Dwyer/Shan/D’Ortona/Maurer/Mitchell/
Olesen/Thiel/Huebner/Gadjeva 
J Innate Immun 2014;6:765–779
DOI: 10.1159/000363242
776
cent values, β = –0.002, t(107) = –2.18, p = 0.03. MIF levels 
also explained a significant proportion of variance in FEV 1 
values, R 2  = 0.04, F(1, 107) = 4.76, p = 0.03.
 Discussion 
 The majority of the currently available data on NET 
proteomes were derived from in vitro studies where neu-
trophils were either stimulated with PMA, cytokines, or 
IgG. To the best of our knowledge, there are no studies 
characterizing the pathogen-induced NET proteomes. 
Here, we provide data that NETs induced by either non-
mucoid or mucoid  P. aeruginosa -strains carried a con-
served core of proteins that were shared, irrespectively of 
the inducing bacterial stimuli. The ‘core proteins’ includ-
ed nucleosome-associated proteins (e.g., histones), struc-
tural proteins (e.g., coronin-1, β-actin, or α-actinin), en-
zymes (e.g., NE, transaldolase, TK, GAPDH, or α-enolase), 
and proteins with antimicrobial activity (e.g., MPO, lyso-
zyme C, lactotransferrin, or azurocidin). While there 
were stimulus-specific proteins, the overall NET pro-
teome did not differ significantly from previously report-
ed PMA  [25, 26] , tumor necrosis factor, and rheumatoid 
factor  [24] proteomes. Cumulatively, these data demon-
strate that NETs harbored a conserved repertoire of in-
nate immune molecules to mediate protection. Irrespec-
tively of the inducing signal (cytokine vs. bacterial stimu-
lation), NETs were decorated with a conserved set of 
proteins that we termed the ‘NET core signature’.
 The presence of the conserved NET-associated pro-
teins prompted us to evaluate whether NET structures 
were present in CF patients. Based on the proteomic find-
ings, we found a significant overlap between the in vitro-
Fig. 6. MIF promotes NET release.  a NETs formed by C57BL6-
derived PMNs in response to  P. aeruginosa PAO1 stimulation. 
NETs were visualized by fluorescent DNA-specific staining with 
SYTOX Green in stimulated neutrophils after fixing and permea-
bilizing. The images were acquired on a Nikon confocal micro-
scope with ×63 and ×40 objectives.  b Stages of nuclear DNA rear-
rangement in response to  P. aeruginosa stimulation of PMNs. The 
‘donut’-shaped nuclei are typical of resting PMNs. ‘Delobulated’ 
and ‘diffuse’ nuclei are characteristic of activated PMNs. NETs are 
elongated DNA-containing structures released by PMNs.  c Pie 
graph representing the percentage of different stages of NETosis 
of PMNs derived from C57BL6 (WT; left pie chart) and MIF KO 
(right pie chart) mice responding to  P. aeruginosa  PAO1 stimula-
tion. Data are representative of 2 experiments.  d Pie graph repre-
senting the percentage of different stages of NETosis of human 
PMNs treated with 50 μ M 4-IPP. The left pie chart represents the 
DMSO-treated PMNs, whereas the right pie chart represents the 
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induced NETs and the DNA-containing complexes in CF 
sputum ( table 1 ). We argue that if the eDNA originated 
from cellular debris, the composition of the DNA-protein 
complexes would be highly variable and no common 
trends could be identified between patients. In contrast, 
the presence of a common protein signature would sug-
gest a specific immune response. The presence of non-
secretory proteins ( table  1 ) within the NET ‘core’ pro-
teome suggested that it is unlikely that the complexes were 
formed between pathogen-derived (naked) eDNA and se-
cretory granules, supporting the argument that the struc-
tures in the CF sputum most likely originated from 
 NETosing cells. These data strengthen previously pub-
lished observations  [8, 9] that demonstrated that 50% of 
the CF sputum-derived DNA is in complex with MPO and 
NE. Cumulatively, these data advocate that a significant 
percent of the eDNA in CF are NETosis derived, provid-
ing a rationale for designing alternative clinical markers to 
monitor CF disease and novel treatment approaches.
 One of the most controversial issues since the discov-
ery of NETosis is whether NETs kill  P. aeruginosa  [2, 27, 
28] . The proposition that NETs have antimicrobial activ-
ity is supported by the broad array of antimicrobial pro-
teins covering NET structures. Given the proteomic data, 
one may assume that the bactericidal properties of NETs 
are mediated by the production of ROS by MPO and 
QSOX1, involve the destruction of bacterial cell wall in-
tegrity by lysozymes, histones, and cathelicidin, and met-
abolic starvation by the creation of local environments 
with low divalent cation abundance (the majority of 
NET-associated proteins are divalent cation chelators, 
e.g. S100A proteins). To address the issue of whether 
 P. aeruginosa withstands NET immunity, we carried out 
experiments using the non-mucoid strain PAO1 and the 
mucoid clinical isolate PA2192 to model the survivabil-
ity of early (non-mucoid) versus late (mucoid) coloniz-
ers, utilizing an experimental approach  [27] that allowed 
us to distinguish between the trapped and killed bacteria. 
Our data reproducibly showed that 50% of  P. aeruginosa 
PAO1 was captured and killed by NETs. In contrast, the 
mucoid 2192 was significantly less susceptible to NET 
capture than the non-mucoid PAO1. These experiments 
produced a novel understanding of the process, as they 
compared bacterial trapping to bacterial killing in the 
presence of NETosis. The resistance of the mucoid  P. ae-
ruginosa  strain to NET adhesion was not due to the over-
expression of alginate, as the mutant  P. aeruginosa strain 
that overexpressed alginate (PA581) was sensitive to 
NET capture and killing (data not shown).
 One important inference of these studies is that, dur-
ing colonization,  P. aeruginosa acquires adaptive muta-
tions that render this pathogen resistant to NET adhesion 
and subsequent killing. It is likely that the selective pres-
sures elicited by MPO-coated NETs drive bacterial path-
oadaptation. The long-lived NET structures in CF pro-
vide a scaffold for  P. aeruginosa deposition and, while 
failing to effectively eradicate the pathogen, are a perfect 
niche to initially promote  P. aeruginosa colonization. 
This process is driven at least partially by the pathogen as 
flagella promotes NETosis. Therefore, destroying NETs 
in CF early in the course of disease might interfere with 
bacterial pathoadaptation.
 It is important to note that not all CF patients benefit 
equally well from Pulmozyme treatment. The use of the 
recombinant human DNase I is accompanied by the re-
lease of active elastase, since the enzyme is released from 
NETs upon DNA cleavage  [8, 9, 36] . The primary targets 
for the liberated elastase are NET-associated histones and 
their subsequent enzymatic digest improves eDNA frag-
mentation  [9] . However, the question remains whether the 
released active elastase should be controlled by addition of 
protease inhibitors  [8, 37] or whether alternative therapies 
that reduce the levels of NETosis should be devised.
 To this end, we report that NETosis was promoted by 
MIF, a cytokine that is released in response to  P. aerugi-










150 Spearman r = –0.2153; p = 0.02
 Fig. 7. Serum MIF levels correlate with decreased lung function. 
Serum MIF levels in 117 CF patients were measured by ELISA. 
FEV 1 percent values are plotted against MIF levels per patient. Lin-
ear regression analysis of the data indicates a mild correlation be-
tween the increased MIF serum levels and lower FEV 1 values (R 2  = 
0.04; p = 0.03). 
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tokine produced by a vast majority of host cells, includ-
ing neutrophils. MIF stimulates MAPK activation by 
binding to CD74 in macrophages or B cells. In addition 
to the CD74 receptor, CXCR2, CXCR4 and CXCR7 were 
implicated as non-cognate MIF receptors on various 
host tissues or cancer cells  [15, 38] . Since neutrophils 
carry CXCR2, but not CD74 or CXCR7, it is possible that 
MIF may trigger CXCR2-driven responses in CF. Be-
cause the ability of neutrophils to NETose depended 
upon the effective blockade of apoptosis and activation 
of MAPK-promoted NETosis, we hypothesized that 
MIF prolonged this process  [22] . In neutrophils, MIF-
regulated pathways are largely unknown, with the ex-
ception of the interesting finding that MIF promoted 
neutrophil survival by inhibiting neutrophil apoptosis 
 [31] . This finding prompted us to evaluate the role of 
MIF in NETosis. We demonstrated that MIF promoted 
MAPK activation and ROS production, potentiating 
NETosis ( fig. 5 ). This observation supported our predic-
tions that prolonged MIF signaling exacerbates CF 
( fig.  7 ). The latter concept is further corroborated by 
data showing that MIF KO mice are less sensitive to 
chronic airway infection by  P. aeruginosa  [39] . The elu-
cidation of MIF as a component of CF pathogenesis pro-
vides a novel therapeutic target that may produce im-
proved outcomes and prognoses for CF.
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